Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older.

@article{Nabhan2005PhaseIP,
  title={Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older.},
  author={Chadi Nabhan and Lynn M Rundhaugen and Mary Beth Riley and Alfred Rademaker and Larry Boehlke and Mashal A Jatoi and Martin S. Tallman},
  journal={Leukemia research},
  year={2005},
  volume={29 1},
  pages={53-7}
}
The prognosis of acute myeloid leukemia (AML) in older adults is generally poor. Standard cytotoxic chemotherapy is usually poorly tolerated and provides dismal results in this patient population. Gemtuzumab ozogamicin (GO) is an immunoconjugate that has activity in the relapsed and refractory setting. We hypothesized that administering this agent, as an initial treatment in AML patients over the age of 65 would have, at least, similar efficacy to standard therapy, but at much less toxicity. We… CONTINUE READING